Cerevance’s First-In-Class Parkinson’s Candidate Shows Phase II Promise

CEO Predicts Annual Revenues Up To $1bn

 
• By Andrew McConaghie

Promising results from a small Phase II study will now propel the company’s CVN424 into pivotal trials, though its optimum dose is still unclear.

Parkinsons Drugs
The drug candidate could be used in combination with existing Parkinson's treatments, such as levadopa, but must first replicate the results in a larger pivotal study. • Source: Alamy

More from R&D

More from Scrip